Samar Mowafy

发表

Lead generation of cysteine based mesenchymal epithelial transition (c-Met) kinase inhibitors: Using structure-based scaffold hopping, 3D-QSAR pharmacophore modeling, virtual screening, molecular docking, and molecular dynamics simulation

N. Farag, A. Raafat, Samar Mowafy, 2022, Comput. Biol. Medicine.

Evaluation of the effectiveness of glutamine in different times of administration in patients undergoing cardiopulmonary bypass during elective cardiac surgeries: randomized controlled study

Samar Mowafy, HebaM Fathi, K. Helmy, 2018 .

Structure-based design generated novel hydroxamic acid based preferential HDAC6 lead inhibitor with on-target cytotoxic activity against primary choroid plexus carcinoma

N. Omar, S. El-Naggar, Samar Mowafy, 2019, Journal of enzyme inhibition and medicinal chemistry.

Design, synthesis and in vitro anti-proliferative activity of 4,6-quinazolinediamines as potent EGFR-TK inhibitors.

K. Abouzid, N. Farag, Samar Mowafy, 2013, European journal of medicinal chemistry.

Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors.

D. Lauffenburger, P. Sorger, N. Gray, 2017, Bioorganic & medicinal chemistry.

Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives.

P. Jänne, N. Farag, K. Abouzid, 2016, Bioorganic & medicinal chemistry.

Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine–hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer

N. Farag, K. Abouzid, Samar Mowafy, 2021, Journal of enzyme inhibition and medicinal chemistry.

3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation.

N. Farag, K. Abouzid, Samar Mowafy, 2019, Bioorganic chemistry.

Structural Basis of Selective Human Indoleamine‐2,3‐dioxygenase 1 (hIDO1) Inhibition

Samar Mowafy, S. E. Kassab, 2021, ChemMedChem.

Insights into flibanserin oxidative stress degradation pathway: in silico – in vitro toxicity assessment of its degradates

Samar Mowafy, M. El-Behairy, I. Abdallah, 2021 .

Studies of TAK 1-centered polypharmacology with novel covalent TAK 1 inhibitors

D. Lauffenburger, P. Sorger, N. Gray, 2017 .

Structure-guided development of covalent TAK1 inhibitors.

P. Sorger, N. Gray, K. Westover, 2017, Bioorganic & medicinal chemistry.

Disease correction in Mucopolysaccharidosis type IIIB mice by intraparenchymal or cisternal delivery of a capsid modified AAV8 codon-optimized NAGLU vector.

C. Heldermon, Samar Mowafy, M. Gelb, 2022, Human molecular genetics.